Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,853
Out of 4,908 analysts
12
Total ratings
n/a
Success rate
-22.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics | Initiates: Hold | $15 | $13.62 | +10.13% | 1 | Jun 11, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $30.95 | +77.71% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.88 | +325.53% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $18.10 | +93.37% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $6.05 | +197.52% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.14 | +122.93% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $6.40 | -6.25% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $8.15 | +206.75% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $70.12 | -68.63% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $22.56 | +6.38% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $11.49 | -12.97% | 1 | Oct 26, 2021 |
Mineralys Therapeutics
Jun 11, 2025
Initiates: Hold
Price Target: $15
Current: $13.62
Upside: +10.13%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $30.95
Upside: +77.71%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.88
Upside: +325.53%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $18.10
Upside: +93.37%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $6.05
Upside: +197.52%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.14
Upside: +122.93%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $6.40
Upside: -6.25%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $8.15
Upside: +206.75%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $70.12
Upside: -68.63%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $22.56
Upside: +6.38%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.49
Upside: -12.97%